|startresults
nifedipine	estrogen	11	12	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
nifedipine	Warfarin	11	9	false	none	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  (See                                       PRECAUTIONS–General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
nifedipine	phenobarbital	11	12	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
nifedipine	cimetidine	11	12	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
nifedipine	clopidogrel bisulfate	11	9	true	positive	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  (See                                       PRECAUTIONS–General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
nifedipine	clopidogrel bisulfate	11	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
nifedipine	clopidogrel bisulfate	11	12	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
nifedipine	clopidogrel bisulfate	11	13	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
nifedipine	theophylline	11	13	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
nifedipine	Clopidogrel bisulfate	11	9	true	positive	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  (See                                       PRECAUTIONS–General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
nifedipine	Clopidogrel bisulfate	11	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
nifedipine	Clopidogrel bisulfate	11	12	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
nifedipine	Clopidogrel bisulfate	11	13	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
nifedipine	warfarin	11	9	false	none	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  (See                                       PRECAUTIONS–General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
nifedipine	digoxin	11	13	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
nifedipine	atenolol	11	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
nifedipine	clopidogrel	11	9	true	positive	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  (See                                       PRECAUTIONS–General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
nifedipine	clopidogrel	11	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
nifedipine	clopidogrel	11	12	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
nifedipine	clopidogrel	11	13	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
estrogen	phenobarbital	12	12	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
estrogen	cimetidine	12	12	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
estrogen	clopidogrel bisulfate	12	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
estrogen	clopidogrel bisulfate	12	12	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
estrogen	clopidogrel bisulfate	12	13	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
estrogen	theophylline	12	13	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
estrogen	Clopidogrel bisulfate	12	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
estrogen	Clopidogrel bisulfate	12	12	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
estrogen	Clopidogrel bisulfate	12	13	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
estrogen	digoxin	12	13	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
estrogen	atenolol	12	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
estrogen	clopidogrel	12	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
estrogen	clopidogrel	12	12	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
estrogen	clopidogrel	12	13	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
estrogen	clopidogrel	12	14	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  	
LMWH	tamoxifen	17	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
LMWH	Warfarin	17	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
LMWH	clopidogrel bisulfate	17	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
LMWH	clopidogrel bisulfate	17	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
LMWH	clopidogrel bisulfate	17	16	false	none	Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
LMWH	torsemide	17	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
LMWH	Clopidogrel bisulfate	17	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
LMWH	Clopidogrel bisulfate	17	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
LMWH	Clopidogrel bisulfate	17	16	false	none	Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
LMWH	warfarin	17	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
LMWH	Heparin	17	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
LMWH	phenytoin	17	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
LMWH	fluvastatin	17	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
LMWH	clopidogrel	17	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
LMWH	clopidogrel	17	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
LMWH	clopidogrel	17	16	false	none	Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
LMWH	clopidogrel	17	18	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  The use of oral anticoagulants, non-study anti-platelet drug and chronic NSAIDs was not allowed in CURE and there are no data on their concomitant use with clopidogrel.  	
LMWH	tolbutamide	17	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
LMWH	heparin	17	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
LMWH	insulin	17	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
LMWH	cholesterol	17	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
tamoxifen	Warfarin	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
tamoxifen	clopidogrel bisulfate	15	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
tamoxifen	clopidogrel bisulfate	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
tamoxifen	clopidogrel bisulfate	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
tamoxifen	clopidogrel bisulfate	15	16	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
tamoxifen	torsemide	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
tamoxifen	theophylline	15	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
tamoxifen	Clopidogrel bisulfate	15	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
tamoxifen	Clopidogrel bisulfate	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
tamoxifen	Clopidogrel bisulfate	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
tamoxifen	Clopidogrel bisulfate	15	16	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
tamoxifen	warfarin	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
tamoxifen	digoxin	15	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
tamoxifen	Heparin	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
tamoxifen	phenytoin	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
tamoxifen	fluvastatin	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
tamoxifen	clopidogrel	15	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
tamoxifen	clopidogrel	15	14	false	none	At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
tamoxifen	clopidogrel	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
tamoxifen	clopidogrel	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
tamoxifen	clopidogrel	15	16	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
tamoxifen	tolbutamide	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
tamoxifen	heparin	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
tamoxifen	insulin	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
tamoxifen	cholesterol	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Warfarin	clopidogrel bisulfate	9	7	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
Warfarin	clopidogrel bisulfate	9	8	false	none	NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
Warfarin	clopidogrel bisulfate	9	9	true	positive	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
Warfarin	clopidogrel bisulfate	9	11	false	none	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  (See                                       PRECAUTIONS–General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
Warfarin	clopidogrel bisulfate	15	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Warfarin	clopidogrel bisulfate	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Warfarin	clopidogrel bisulfate	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Warfarin	clopidogrel bisulfate	15	16	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
Warfarin	torsemide	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Warfarin	theophylline	15	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Warfarin	Clopidogrel bisulfate	9	7	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
Warfarin	Clopidogrel bisulfate	9	8	false	none	NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
Warfarin	Clopidogrel bisulfate	9	9	true	positive	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
Warfarin	Clopidogrel bisulfate	9	11	false	none	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  (See                                       PRECAUTIONS–General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
Warfarin	Clopidogrel bisulfate	15	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Warfarin	Clopidogrel bisulfate	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Warfarin	Clopidogrel bisulfate	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Warfarin	Clopidogrel bisulfate	15	16	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
Warfarin	warfarin	9	9	true	positive	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
Warfarin	warfarin	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Warfarin	digoxin	15	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Warfarin	naproxen	9	7	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
Warfarin	atenolol	9	11	false	none	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  (See                                       PRECAUTIONS–General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
Warfarin	Heparin	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Warfarin	phenytoin	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Warfarin	fluvastatin	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Warfarin	clopidogrel	9	7	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
Warfarin	clopidogrel	9	8	false	none	NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
Warfarin	clopidogrel	9	9	true	positive	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
Warfarin	clopidogrel	9	11	false	none	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  (See                                       PRECAUTIONS–General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
Warfarin	clopidogrel	15	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Warfarin	clopidogrel	15	14	false	none	At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Warfarin	clopidogrel	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Warfarin	clopidogrel	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Warfarin	clopidogrel	15	16	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
Warfarin	tolbutamide	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Warfarin	heparin	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Warfarin	insulin	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Warfarin	cholesterol	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
phenobarbital	cimetidine	12	12	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
phenobarbital	clopidogrel bisulfate	12	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
phenobarbital	clopidogrel bisulfate	12	12	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
phenobarbital	clopidogrel bisulfate	12	13	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
phenobarbital	theophylline	12	13	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
phenobarbital	Clopidogrel bisulfate	12	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
phenobarbital	Clopidogrel bisulfate	12	12	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
phenobarbital	Clopidogrel bisulfate	12	13	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
phenobarbital	digoxin	12	13	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
phenobarbital	atenolol	12	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
phenobarbital	clopidogrel	12	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
phenobarbital	clopidogrel	12	12	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
phenobarbital	clopidogrel	12	13	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
phenobarbital	clopidogrel	12	14	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  	
cimetidine	clopidogrel bisulfate	12	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
cimetidine	clopidogrel bisulfate	12	12	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
cimetidine	clopidogrel bisulfate	12	13	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
cimetidine	theophylline	12	13	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
cimetidine	Clopidogrel bisulfate	12	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
cimetidine	Clopidogrel bisulfate	12	12	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
cimetidine	Clopidogrel bisulfate	12	13	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
cimetidine	digoxin	12	13	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
cimetidine	atenolol	12	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
cimetidine	clopidogrel	12	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
cimetidine	clopidogrel	12	12	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
cimetidine	clopidogrel	12	13	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
cimetidine	clopidogrel	12	14	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  	
clopidogrel bisulfate	torsemide	13	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
clopidogrel bisulfate	torsemide	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
clopidogrel bisulfate	torsemide	17	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel bisulfate	torsemide	16	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
clopidogrel bisulfate	theophylline	11	13	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
clopidogrel bisulfate	theophylline	12	13	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
clopidogrel bisulfate	theophylline	13	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
clopidogrel bisulfate	theophylline	15	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
clopidogrel bisulfate	Clopidogrel bisulfate	2	2	true	negative	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  	
clopidogrel bisulfate	Clopidogrel bisulfate	2	3	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
clopidogrel bisulfate	Clopidogrel bisulfate	2	4	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
clopidogrel bisulfate	Clopidogrel bisulfate	3	2	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
clopidogrel bisulfate	Clopidogrel bisulfate	3	3	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
clopidogrel bisulfate	Clopidogrel bisulfate	3	4	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
clopidogrel bisulfate	Clopidogrel bisulfate	3	5	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
clopidogrel bisulfate	Clopidogrel bisulfate	4	2	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
clopidogrel bisulfate	Clopidogrel bisulfate	4	3	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
clopidogrel bisulfate	Clopidogrel bisulfate	4	4	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
clopidogrel bisulfate	Clopidogrel bisulfate	4	5	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
clopidogrel bisulfate	Clopidogrel bisulfate	4	6	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
clopidogrel bisulfate	Clopidogrel bisulfate	5	3	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
clopidogrel bisulfate	Clopidogrel bisulfate	5	4	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
clopidogrel bisulfate	Clopidogrel bisulfate	5	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
clopidogrel bisulfate	Clopidogrel bisulfate	5	6	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
clopidogrel bisulfate	Clopidogrel bisulfate	5	7	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
clopidogrel bisulfate	Clopidogrel bisulfate	6	4	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
clopidogrel bisulfate	Clopidogrel bisulfate	6	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
clopidogrel bisulfate	Clopidogrel bisulfate	6	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
clopidogrel bisulfate	Clopidogrel bisulfate	6	7	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
clopidogrel bisulfate	Clopidogrel bisulfate	6	8	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  	
clopidogrel bisulfate	Clopidogrel bisulfate	7	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
clopidogrel bisulfate	Clopidogrel bisulfate	7	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
clopidogrel bisulfate	Clopidogrel bisulfate	7	7	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
clopidogrel bisulfate	Clopidogrel bisulfate	7	8	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  	
clopidogrel bisulfate	Clopidogrel bisulfate	7	9	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
clopidogrel bisulfate	Clopidogrel bisulfate	8	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  	
clopidogrel bisulfate	Clopidogrel bisulfate	8	7	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  	
clopidogrel bisulfate	Clopidogrel bisulfate	8	8	false	none	NSAIDs and clopidogrel bisulfate should be coadministered with caution.  	
clopidogrel bisulfate	Clopidogrel bisulfate	8	9	false	none	NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
clopidogrel bisulfate	Clopidogrel bisulfate	9	7	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
clopidogrel bisulfate	Clopidogrel bisulfate	9	8	false	none	NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
clopidogrel bisulfate	Clopidogrel bisulfate	9	9	true	positive	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
clopidogrel bisulfate	Clopidogrel bisulfate	9	11	false	none	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  (See                                       PRECAUTIONS–General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
clopidogrel bisulfate	Clopidogrel bisulfate	11	9	false	none	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  (See                                       PRECAUTIONS–General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
clopidogrel bisulfate	Clopidogrel bisulfate	11	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
clopidogrel bisulfate	Clopidogrel bisulfate	11	12	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
clopidogrel bisulfate	Clopidogrel bisulfate	11	13	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
clopidogrel bisulfate	Clopidogrel bisulfate	12	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
clopidogrel bisulfate	Clopidogrel bisulfate	12	12	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
clopidogrel bisulfate	Clopidogrel bisulfate	12	13	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
clopidogrel bisulfate	Clopidogrel bisulfate	13	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
clopidogrel bisulfate	Clopidogrel bisulfate	13	12	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
clopidogrel bisulfate	Clopidogrel bisulfate	13	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
clopidogrel bisulfate	Clopidogrel bisulfate	13	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
clopidogrel bisulfate	Clopidogrel bisulfate	15	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
clopidogrel bisulfate	Clopidogrel bisulfate	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
clopidogrel bisulfate	Clopidogrel bisulfate	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel bisulfate	Clopidogrel bisulfate	15	16	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
clopidogrel bisulfate	Clopidogrel bisulfate	17	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel bisulfate	Clopidogrel bisulfate	17	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel bisulfate	Clopidogrel bisulfate	17	16	false	none	Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel bisulfate	Clopidogrel bisulfate	16	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
clopidogrel bisulfate	Clopidogrel bisulfate	16	17	false	none	Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel bisulfate	Clopidogrel bisulfate	16	16	false	none	Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
clopidogrel bisulfate	warfarin	7	9	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
clopidogrel bisulfate	warfarin	8	9	false	none	NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
clopidogrel bisulfate	warfarin	9	9	true	positive	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
clopidogrel bisulfate	warfarin	11	9	false	none	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  (See                                       PRECAUTIONS–General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
clopidogrel bisulfate	warfarin	13	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
clopidogrel bisulfate	warfarin	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
clopidogrel bisulfate	warfarin	17	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel bisulfate	warfarin	16	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
clopidogrel bisulfate	digoxin	11	13	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
clopidogrel bisulfate	digoxin	12	13	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
clopidogrel bisulfate	digoxin	13	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
clopidogrel bisulfate	digoxin	15	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
clopidogrel bisulfate	naproxen	5	7	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
clopidogrel bisulfate	naproxen	6	7	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
clopidogrel bisulfate	naproxen	7	7	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
clopidogrel bisulfate	naproxen	8	7	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  	
clopidogrel bisulfate	naproxen	9	7	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
clopidogrel bisulfate	atenolol	9	11	true	positive	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  (See                                       PRECAUTIONS–General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
clopidogrel bisulfate	atenolol	11	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
clopidogrel bisulfate	atenolol	12	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
clopidogrel bisulfate	atenolol	13	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
clopidogrel bisulfate	Aspirin	2	1	false	none	Drug Interactions                                                 Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  	
clopidogrel bisulfate	Aspirin	2	2	true	negative	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  	
clopidogrel bisulfate	Aspirin	2	3	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
clopidogrel bisulfate	Aspirin	2	4	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
clopidogrel bisulfate	Aspirin	3	1	false	none	Drug Interactions                                                 Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
clopidogrel bisulfate	Aspirin	3	2	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
clopidogrel bisulfate	Aspirin	3	3	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
clopidogrel bisulfate	Aspirin	3	4	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
clopidogrel bisulfate	Aspirin	4	2	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
clopidogrel bisulfate	Aspirin	4	3	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
clopidogrel bisulfate	Aspirin	4	4	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
clopidogrel bisulfate	Aspirin	5	3	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
clopidogrel bisulfate	Aspirin	5	4	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
clopidogrel bisulfate	Aspirin	6	4	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
clopidogrel bisulfate	aspirin	2	1	false	none	Drug Interactions                                                 Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  	
clopidogrel bisulfate	aspirin	2	2	true	negative	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  	
clopidogrel bisulfate	aspirin	2	3	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
clopidogrel bisulfate	aspirin	2	4	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
clopidogrel bisulfate	aspirin	3	1	false	none	Drug Interactions                                                 Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
clopidogrel bisulfate	aspirin	3	2	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
clopidogrel bisulfate	aspirin	3	3	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
clopidogrel bisulfate	aspirin	3	4	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
clopidogrel bisulfate	aspirin	4	2	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
clopidogrel bisulfate	aspirin	4	3	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
clopidogrel bisulfate	aspirin	4	4	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
clopidogrel bisulfate	aspirin	5	3	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
clopidogrel bisulfate	aspirin	5	4	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
clopidogrel bisulfate	aspirin	6	4	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
clopidogrel bisulfate	Heparin	3	5	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
clopidogrel bisulfate	Heparin	4	5	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
clopidogrel bisulfate	Heparin	4	6	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
clopidogrel bisulfate	Heparin	5	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
clopidogrel bisulfate	Heparin	5	6	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
clopidogrel bisulfate	Heparin	6	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
clopidogrel bisulfate	Heparin	6	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
clopidogrel bisulfate	Heparin	7	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
clopidogrel bisulfate	Heparin	7	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
clopidogrel bisulfate	Heparin	8	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  	
clopidogrel bisulfate	Heparin	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel bisulfate	Heparin	17	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel bisulfate	Heparin	16	17	false	none	Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel bisulfate	phenytoin	13	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
clopidogrel bisulfate	phenytoin	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
clopidogrel bisulfate	phenytoin	17	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel bisulfate	phenytoin	16	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
clopidogrel bisulfate	fluvastatin	13	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
clopidogrel bisulfate	fluvastatin	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
clopidogrel bisulfate	fluvastatin	17	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel bisulfate	fluvastatin	16	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
clopidogrel bisulfate	clopidogrel	2	1	false	none	Drug Interactions                                                 Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  	
clopidogrel bisulfate	clopidogrel	2	2	true	negative	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  	
clopidogrel bisulfate	clopidogrel	2	3	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
clopidogrel bisulfate	clopidogrel	2	4	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
clopidogrel bisulfate	clopidogrel	3	1	false	none	Drug Interactions                                                 Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
clopidogrel bisulfate	clopidogrel	3	2	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
clopidogrel bisulfate	clopidogrel	3	3	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
clopidogrel bisulfate	clopidogrel	3	4	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
clopidogrel bisulfate	clopidogrel	3	5	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
clopidogrel bisulfate	clopidogrel	4	2	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
clopidogrel bisulfate	clopidogrel	4	3	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
clopidogrel bisulfate	clopidogrel	4	4	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
clopidogrel bisulfate	clopidogrel	4	5	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
clopidogrel bisulfate	clopidogrel	4	6	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
clopidogrel bisulfate	clopidogrel	5	3	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
clopidogrel bisulfate	clopidogrel	5	4	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
clopidogrel bisulfate	clopidogrel	5	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
clopidogrel bisulfate	clopidogrel	5	6	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
clopidogrel bisulfate	clopidogrel	5	7	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
clopidogrel bisulfate	clopidogrel	6	4	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
clopidogrel bisulfate	clopidogrel	6	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
clopidogrel bisulfate	clopidogrel	6	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
clopidogrel bisulfate	clopidogrel	6	7	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
clopidogrel bisulfate	clopidogrel	6	8	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  	
clopidogrel bisulfate	clopidogrel	7	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
clopidogrel bisulfate	clopidogrel	7	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
clopidogrel bisulfate	clopidogrel	7	7	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
clopidogrel bisulfate	clopidogrel	7	8	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  	
clopidogrel bisulfate	clopidogrel	7	9	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
clopidogrel bisulfate	clopidogrel	8	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  	
clopidogrel bisulfate	clopidogrel	8	7	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  	
clopidogrel bisulfate	clopidogrel	8	8	false	none	NSAIDs and clopidogrel bisulfate should be coadministered with caution.  	
clopidogrel bisulfate	clopidogrel	8	9	false	none	NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
clopidogrel bisulfate	clopidogrel	9	7	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
clopidogrel bisulfate	clopidogrel	9	8	false	none	NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
clopidogrel bisulfate	clopidogrel	9	9	true	positive	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
clopidogrel bisulfate	clopidogrel	9	11	false	none	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  (See                                       PRECAUTIONS–General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
clopidogrel bisulfate	clopidogrel	11	9	false	none	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  (See                                       PRECAUTIONS–General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
clopidogrel bisulfate	clopidogrel	11	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
clopidogrel bisulfate	clopidogrel	11	12	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
clopidogrel bisulfate	clopidogrel	11	13	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
clopidogrel bisulfate	clopidogrel	12	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
clopidogrel bisulfate	clopidogrel	12	12	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
clopidogrel bisulfate	clopidogrel	12	13	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
clopidogrel bisulfate	clopidogrel	12	14	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  	
clopidogrel bisulfate	clopidogrel	13	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
clopidogrel bisulfate	clopidogrel	13	12	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
clopidogrel bisulfate	clopidogrel	13	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
clopidogrel bisulfate	clopidogrel	13	14	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  	
clopidogrel bisulfate	clopidogrel	13	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
clopidogrel bisulfate	clopidogrel	15	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
clopidogrel bisulfate	clopidogrel	15	14	false	none	At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
clopidogrel bisulfate	clopidogrel	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
clopidogrel bisulfate	clopidogrel	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel bisulfate	clopidogrel	15	16	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
clopidogrel bisulfate	clopidogrel	17	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel bisulfate	clopidogrel	17	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel bisulfate	clopidogrel	17	16	false	none	Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel bisulfate	clopidogrel	17	18	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  The use of oral anticoagulants, non-study anti-platelet drug and chronic NSAIDs was not allowed in CURE and there are no data on their concomitant use with clopidogrel.  	
clopidogrel bisulfate	clopidogrel	16	14	false	none	At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
clopidogrel bisulfate	clopidogrel	16	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
clopidogrel bisulfate	clopidogrel	16	17	false	none	Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel bisulfate	clopidogrel	16	16	false	none	Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
clopidogrel bisulfate	clopidogrel	16	18	false	none	Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  The use of oral anticoagulants, non-study anti-platelet drug and chronic NSAIDs was not allowed in CURE and there are no data on their concomitant use with clopidogrel.  	
clopidogrel bisulfate	tolbutamide	13	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
clopidogrel bisulfate	tolbutamide	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
clopidogrel bisulfate	tolbutamide	17	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel bisulfate	tolbutamide	16	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
clopidogrel bisulfate	heparin	3	5	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
clopidogrel bisulfate	heparin	4	5	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
clopidogrel bisulfate	heparin	4	6	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
clopidogrel bisulfate	heparin	5	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
clopidogrel bisulfate	heparin	5	6	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
clopidogrel bisulfate	heparin	6	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
clopidogrel bisulfate	heparin	6	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
clopidogrel bisulfate	heparin	7	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
clopidogrel bisulfate	heparin	7	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
clopidogrel bisulfate	heparin	8	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  	
clopidogrel bisulfate	heparin	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel bisulfate	heparin	17	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel bisulfate	heparin	16	17	false	none	Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel bisulfate	insulin	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel bisulfate	insulin	17	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel bisulfate	insulin	16	17	false	none	Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel bisulfate	cholesterol	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel bisulfate	cholesterol	17	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel bisulfate	cholesterol	16	17	false	none	Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
torsemide	theophylline	15	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
torsemide	Clopidogrel bisulfate	15	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
torsemide	Clopidogrel bisulfate	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
torsemide	Clopidogrel bisulfate	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
torsemide	Clopidogrel bisulfate	15	16	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
torsemide	warfarin	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
torsemide	digoxin	15	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
torsemide	Heparin	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
torsemide	phenytoin	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
torsemide	fluvastatin	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
torsemide	clopidogrel	15	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
torsemide	clopidogrel	15	14	false	none	At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
torsemide	clopidogrel	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
torsemide	clopidogrel	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
torsemide	clopidogrel	15	16	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
torsemide	tolbutamide	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
torsemide	heparin	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
torsemide	insulin	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
torsemide	cholesterol	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
theophylline	Clopidogrel bisulfate	13	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
theophylline	Clopidogrel bisulfate	13	12	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
theophylline	Clopidogrel bisulfate	13	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
theophylline	Clopidogrel bisulfate	13	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
theophylline	warfarin	13	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
theophylline	digoxin	13	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
theophylline	atenolol	13	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
theophylline	phenytoin	13	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
theophylline	fluvastatin	13	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
theophylline	clopidogrel	13	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
theophylline	clopidogrel	13	12	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
theophylline	clopidogrel	13	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
theophylline	clopidogrel	13	14	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  	
theophylline	clopidogrel	13	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
theophylline	tolbutamide	13	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Clopidogrel bisulfate	warfarin	7	9	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
Clopidogrel bisulfate	warfarin	8	9	false	none	NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
Clopidogrel bisulfate	warfarin	9	9	true	positive	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
Clopidogrel bisulfate	warfarin	11	9	false	none	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  (See                                       PRECAUTIONS–General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
Clopidogrel bisulfate	warfarin	13	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Clopidogrel bisulfate	warfarin	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Clopidogrel bisulfate	warfarin	17	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Clopidogrel bisulfate	warfarin	16	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
Clopidogrel bisulfate	digoxin	11	13	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
Clopidogrel bisulfate	digoxin	12	13	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
Clopidogrel bisulfate	digoxin	13	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
Clopidogrel bisulfate	digoxin	15	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Clopidogrel bisulfate	naproxen	5	7	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
Clopidogrel bisulfate	naproxen	6	7	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
Clopidogrel bisulfate	naproxen	7	7	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
Clopidogrel bisulfate	naproxen	8	7	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  	
Clopidogrel bisulfate	naproxen	9	7	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
Clopidogrel bisulfate	atenolol	9	11	true	positive	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  (See                                       PRECAUTIONS–General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
Clopidogrel bisulfate	atenolol	11	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
Clopidogrel bisulfate	atenolol	12	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
Clopidogrel bisulfate	atenolol	13	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
Clopidogrel bisulfate	Aspirin	2	1	false	none	Drug Interactions                                                 Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  	
Clopidogrel bisulfate	Aspirin	2	2	true	negative	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  	
Clopidogrel bisulfate	Aspirin	2	3	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Clopidogrel bisulfate	Aspirin	2	4	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
Clopidogrel bisulfate	Aspirin	3	1	false	none	Drug Interactions                                                 Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Clopidogrel bisulfate	Aspirin	3	2	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Clopidogrel bisulfate	Aspirin	3	3	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Clopidogrel bisulfate	Aspirin	3	4	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
Clopidogrel bisulfate	Aspirin	4	2	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
Clopidogrel bisulfate	Aspirin	4	3	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
Clopidogrel bisulfate	Aspirin	4	4	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
Clopidogrel bisulfate	Aspirin	5	3	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Clopidogrel bisulfate	Aspirin	5	4	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Clopidogrel bisulfate	Aspirin	6	4	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
Clopidogrel bisulfate	aspirin	2	1	false	none	Drug Interactions                                                 Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  	
Clopidogrel bisulfate	aspirin	2	2	true	negative	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  	
Clopidogrel bisulfate	aspirin	2	3	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Clopidogrel bisulfate	aspirin	2	4	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
Clopidogrel bisulfate	aspirin	3	1	false	none	Drug Interactions                                                 Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Clopidogrel bisulfate	aspirin	3	2	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Clopidogrel bisulfate	aspirin	3	3	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Clopidogrel bisulfate	aspirin	3	4	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
Clopidogrel bisulfate	aspirin	4	2	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
Clopidogrel bisulfate	aspirin	4	3	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
Clopidogrel bisulfate	aspirin	4	4	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
Clopidogrel bisulfate	aspirin	5	3	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Clopidogrel bisulfate	aspirin	5	4	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Clopidogrel bisulfate	aspirin	6	4	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
Clopidogrel bisulfate	Heparin	3	5	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Clopidogrel bisulfate	Heparin	4	5	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Clopidogrel bisulfate	Heparin	4	6	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
Clopidogrel bisulfate	Heparin	5	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Clopidogrel bisulfate	Heparin	5	6	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
Clopidogrel bisulfate	Heparin	6	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
Clopidogrel bisulfate	Heparin	6	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
Clopidogrel bisulfate	Heparin	7	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
Clopidogrel bisulfate	Heparin	7	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
Clopidogrel bisulfate	Heparin	8	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  	
Clopidogrel bisulfate	Heparin	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Clopidogrel bisulfate	Heparin	17	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Clopidogrel bisulfate	Heparin	16	17	false	none	Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Clopidogrel bisulfate	phenytoin	13	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Clopidogrel bisulfate	phenytoin	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Clopidogrel bisulfate	phenytoin	17	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Clopidogrel bisulfate	phenytoin	16	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
Clopidogrel bisulfate	fluvastatin	13	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Clopidogrel bisulfate	fluvastatin	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Clopidogrel bisulfate	fluvastatin	17	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Clopidogrel bisulfate	fluvastatin	16	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
Clopidogrel bisulfate	clopidogrel	2	1	false	none	Drug Interactions                                                 Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  	
Clopidogrel bisulfate	clopidogrel	2	2	true	negative	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  	
Clopidogrel bisulfate	clopidogrel	2	3	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Clopidogrel bisulfate	clopidogrel	2	4	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
Clopidogrel bisulfate	clopidogrel	3	1	false	none	Drug Interactions                                                 Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Clopidogrel bisulfate	clopidogrel	3	2	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Clopidogrel bisulfate	clopidogrel	3	3	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Clopidogrel bisulfate	clopidogrel	3	4	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
Clopidogrel bisulfate	clopidogrel	3	5	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Clopidogrel bisulfate	clopidogrel	4	2	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
Clopidogrel bisulfate	clopidogrel	4	3	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
Clopidogrel bisulfate	clopidogrel	4	4	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
Clopidogrel bisulfate	clopidogrel	4	5	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Clopidogrel bisulfate	clopidogrel	4	6	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
Clopidogrel bisulfate	clopidogrel	5	3	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Clopidogrel bisulfate	clopidogrel	5	4	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Clopidogrel bisulfate	clopidogrel	5	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Clopidogrel bisulfate	clopidogrel	5	6	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
Clopidogrel bisulfate	clopidogrel	5	7	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
Clopidogrel bisulfate	clopidogrel	6	4	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
Clopidogrel bisulfate	clopidogrel	6	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
Clopidogrel bisulfate	clopidogrel	6	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
Clopidogrel bisulfate	clopidogrel	6	7	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
Clopidogrel bisulfate	clopidogrel	6	8	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  	
Clopidogrel bisulfate	clopidogrel	7	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
Clopidogrel bisulfate	clopidogrel	7	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
Clopidogrel bisulfate	clopidogrel	7	7	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
Clopidogrel bisulfate	clopidogrel	7	8	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  	
Clopidogrel bisulfate	clopidogrel	7	9	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
Clopidogrel bisulfate	clopidogrel	8	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  	
Clopidogrel bisulfate	clopidogrel	8	7	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  	
Clopidogrel bisulfate	clopidogrel	8	8	false	none	NSAIDs and clopidogrel bisulfate should be coadministered with caution.  	
Clopidogrel bisulfate	clopidogrel	8	9	false	none	NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
Clopidogrel bisulfate	clopidogrel	9	7	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
Clopidogrel bisulfate	clopidogrel	9	8	false	none	NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
Clopidogrel bisulfate	clopidogrel	9	9	true	positive	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
Clopidogrel bisulfate	clopidogrel	9	11	false	none	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  (See                                       PRECAUTIONS–General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
Clopidogrel bisulfate	clopidogrel	11	9	false	none	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  (See                                       PRECAUTIONS–General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
Clopidogrel bisulfate	clopidogrel	11	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
Clopidogrel bisulfate	clopidogrel	11	12	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
Clopidogrel bisulfate	clopidogrel	11	13	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
Clopidogrel bisulfate	clopidogrel	12	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
Clopidogrel bisulfate	clopidogrel	12	12	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
Clopidogrel bisulfate	clopidogrel	12	13	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
Clopidogrel bisulfate	clopidogrel	12	14	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  	
Clopidogrel bisulfate	clopidogrel	13	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
Clopidogrel bisulfate	clopidogrel	13	12	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
Clopidogrel bisulfate	clopidogrel	13	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
Clopidogrel bisulfate	clopidogrel	13	14	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  	
Clopidogrel bisulfate	clopidogrel	13	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Clopidogrel bisulfate	clopidogrel	15	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Clopidogrel bisulfate	clopidogrel	15	14	false	none	At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Clopidogrel bisulfate	clopidogrel	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Clopidogrel bisulfate	clopidogrel	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Clopidogrel bisulfate	clopidogrel	15	16	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
Clopidogrel bisulfate	clopidogrel	17	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Clopidogrel bisulfate	clopidogrel	17	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Clopidogrel bisulfate	clopidogrel	17	16	false	none	Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Clopidogrel bisulfate	clopidogrel	17	18	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  The use of oral anticoagulants, non-study anti-platelet drug and chronic NSAIDs was not allowed in CURE and there are no data on their concomitant use with clopidogrel.  	
Clopidogrel bisulfate	clopidogrel	16	14	false	none	At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
Clopidogrel bisulfate	clopidogrel	16	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
Clopidogrel bisulfate	clopidogrel	16	17	false	none	Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Clopidogrel bisulfate	clopidogrel	16	16	false	none	Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
Clopidogrel bisulfate	clopidogrel	16	18	false	none	Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  The use of oral anticoagulants, non-study anti-platelet drug and chronic NSAIDs was not allowed in CURE and there are no data on their concomitant use with clopidogrel.  	
Clopidogrel bisulfate	tolbutamide	13	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Clopidogrel bisulfate	tolbutamide	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
Clopidogrel bisulfate	tolbutamide	17	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Clopidogrel bisulfate	tolbutamide	16	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
Clopidogrel bisulfate	heparin	3	5	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Clopidogrel bisulfate	heparin	4	5	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Clopidogrel bisulfate	heparin	4	6	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
Clopidogrel bisulfate	heparin	5	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Clopidogrel bisulfate	heparin	5	6	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
Clopidogrel bisulfate	heparin	6	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
Clopidogrel bisulfate	heparin	6	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
Clopidogrel bisulfate	heparin	7	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
Clopidogrel bisulfate	heparin	7	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
Clopidogrel bisulfate	heparin	8	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  	
Clopidogrel bisulfate	heparin	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Clopidogrel bisulfate	heparin	17	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Clopidogrel bisulfate	heparin	16	17	false	none	Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Clopidogrel bisulfate	insulin	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Clopidogrel bisulfate	insulin	17	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Clopidogrel bisulfate	insulin	16	17	false	none	Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Clopidogrel bisulfate	cholesterol	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Clopidogrel bisulfate	cholesterol	17	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Clopidogrel bisulfate	cholesterol	16	17	false	none	Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
warfarin	digoxin	15	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
warfarin	naproxen	9	7	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
warfarin	atenolol	9	11	false	none	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  (See                                       PRECAUTIONS–General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
warfarin	Heparin	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
warfarin	phenytoin	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
warfarin	fluvastatin	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
warfarin	clopidogrel	9	7	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
warfarin	clopidogrel	9	8	false	none	NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
warfarin	clopidogrel	9	9	true	positive	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
warfarin	clopidogrel	9	11	false	none	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  (See                                       PRECAUTIONS–General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
warfarin	clopidogrel	15	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
warfarin	clopidogrel	15	14	false	none	At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
warfarin	clopidogrel	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
warfarin	clopidogrel	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
warfarin	clopidogrel	15	16	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
warfarin	tolbutamide	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
warfarin	heparin	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
warfarin	insulin	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
warfarin	cholesterol	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
digoxin	atenolol	13	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
digoxin	phenytoin	13	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
digoxin	fluvastatin	13	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
digoxin	clopidogrel	13	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
digoxin	clopidogrel	13	12	false	none	The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
digoxin	clopidogrel	13	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
digoxin	clopidogrel	13	14	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  	
digoxin	clopidogrel	13	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
digoxin	tolbutamide	13	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
naproxen	Heparin	7	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
naproxen	Heparin	7	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
naproxen	clopidogrel	7	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
naproxen	clopidogrel	7	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
naproxen	clopidogrel	7	7	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
naproxen	clopidogrel	7	8	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  	
naproxen	clopidogrel	7	9	true	positive	Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  	
naproxen	heparin	7	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
naproxen	heparin	7	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
atenolol	clopidogrel	11	9	true	positive	Warfarin                                                             Because of the increased risk of bleeding, the concomitant administration of warfarin with clopidogrel bisulfate should be undertaken with caution.  (See                                       PRECAUTIONS–General                                   .)  Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
atenolol	clopidogrel	11	11	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  	
atenolol	clopidogrel	11	12	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  	
atenolol	clopidogrel	11	13	false	none	Other Concomitant Therapy                                                             No clinically significant pharmacodynamic interactions were observed when clopidogrel bisulfate was coadministered with atenolol, nifedipine, or both atenolol and nifedipine.  The pharmacodynamic activity of clopidogrel bisulfate was also not significantly influenced by the coadministration of phenobarbital, cimetidine or estrogen.  The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  	
Aspirin	aspirin	1	1	false	none	Drug Interactions                                                 Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  	
Aspirin	aspirin	1	2	false	none	Drug Interactions                                                 Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  	
Aspirin	aspirin	1	3	false	none	Drug Interactions                                                 Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Aspirin	aspirin	2	1	false	none	Drug Interactions                                                 Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  	
Aspirin	aspirin	2	2	true	negative	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  	
Aspirin	aspirin	2	3	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Aspirin	aspirin	2	4	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
Aspirin	aspirin	3	1	false	none	Drug Interactions                                                 Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Aspirin	aspirin	3	2	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Aspirin	aspirin	3	3	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Aspirin	aspirin	3	4	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
Aspirin	aspirin	4	2	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
Aspirin	aspirin	4	3	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
Aspirin	aspirin	4	4	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
Aspirin	Heparin	3	5	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Aspirin	Heparin	4	5	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Aspirin	Heparin	4	6	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
Aspirin	clopidogrel	1	1	false	none	Drug Interactions                                                 Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  	
Aspirin	clopidogrel	1	2	false	none	Drug Interactions                                                 Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  	
Aspirin	clopidogrel	1	3	false	none	Drug Interactions                                                 Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Aspirin	clopidogrel	2	1	false	none	Drug Interactions                                                 Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  	
Aspirin	clopidogrel	2	2	true	negative	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  	
Aspirin	clopidogrel	2	3	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Aspirin	clopidogrel	2	4	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
Aspirin	clopidogrel	3	1	false	none	Drug Interactions                                                 Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Aspirin	clopidogrel	3	2	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Aspirin	clopidogrel	3	3	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
Aspirin	clopidogrel	3	4	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
Aspirin	clopidogrel	3	5	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Aspirin	clopidogrel	4	2	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
Aspirin	clopidogrel	4	3	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
Aspirin	clopidogrel	4	4	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
Aspirin	clopidogrel	4	5	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Aspirin	clopidogrel	4	6	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
Aspirin	heparin	3	5	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Aspirin	heparin	4	5	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Aspirin	heparin	4	6	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
aspirin	Heparin	3	5	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
aspirin	Heparin	4	5	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
aspirin	Heparin	4	6	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
aspirin	clopidogrel	1	1	false	none	Drug Interactions                                                 Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  	
aspirin	clopidogrel	1	2	false	none	Drug Interactions                                                 Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  	
aspirin	clopidogrel	1	3	false	none	Drug Interactions                                                 Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
aspirin	clopidogrel	2	1	false	none	Drug Interactions                                                 Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  	
aspirin	clopidogrel	2	2	true	negative	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  	
aspirin	clopidogrel	2	3	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
aspirin	clopidogrel	2	4	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
aspirin	clopidogrel	3	1	false	none	Drug Interactions                                                 Study of specific drug interactions yielded the following results:                                                                                                                                                                                      Aspirin                                                             Aspirin did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation.  Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
aspirin	clopidogrel	3	2	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
aspirin	clopidogrel	3	3	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  	
aspirin	clopidogrel	3	4	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
aspirin	clopidogrel	3	5	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
aspirin	clopidogrel	4	2	false	none	Concomitant administration of 500 mg of aspirin twice a day for 1 day did not significantly increase the prolongation of bleeding time induced by clopidogrel bisulfate.  Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
aspirin	clopidogrel	4	3	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
aspirin	clopidogrel	4	4	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  	
aspirin	clopidogrel	4	5	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
aspirin	clopidogrel	4	6	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
aspirin	heparin	3	5	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
aspirin	heparin	4	5	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
aspirin	heparin	4	6	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
Heparin	phenytoin	17	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Heparin	fluvastatin	17	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Heparin	clopidogrel	17	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Heparin	clopidogrel	17	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Heparin	clopidogrel	17	16	false	none	Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Heparin	clopidogrel	17	18	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  The use of oral anticoagulants, non-study anti-platelet drug and chronic NSAIDs was not allowed in CURE and there are no data on their concomitant use with clopidogrel.  	
Heparin	clopidogrel	5	3	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Heparin	clopidogrel	5	4	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Heparin	clopidogrel	5	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Heparin	clopidogrel	5	6	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
Heparin	clopidogrel	5	7	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
Heparin	clopidogrel	6	4	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
Heparin	clopidogrel	6	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
Heparin	clopidogrel	6	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
Heparin	clopidogrel	6	7	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
Heparin	clopidogrel	6	8	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  	
Heparin	tolbutamide	17	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Heparin	heparin	17	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Heparin	heparin	5	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
Heparin	heparin	5	6	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
Heparin	heparin	6	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
Heparin	heparin	6	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
Heparin	insulin	17	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
Heparin	cholesterol	17	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
phenytoin	fluvastatin	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
phenytoin	clopidogrel	15	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
phenytoin	clopidogrel	15	14	false	none	At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
phenytoin	clopidogrel	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
phenytoin	clopidogrel	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
phenytoin	clopidogrel	15	16	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
phenytoin	tolbutamide	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
phenytoin	heparin	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
phenytoin	insulin	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
phenytoin	cholesterol	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
fluvastatin	clopidogrel	15	13	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
fluvastatin	clopidogrel	15	14	false	none	At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
fluvastatin	clopidogrel	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
fluvastatin	clopidogrel	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
fluvastatin	clopidogrel	15	16	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
fluvastatin	tolbutamide	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
fluvastatin	heparin	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
fluvastatin	insulin	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
fluvastatin	cholesterol	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel	tolbutamide	13	15	false	none	The pharmacokinetics of digoxin or theophylline were not modified by the coadministration of clopidogrel bisulfate.  At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
clopidogrel	tolbutamide	14	15	false	none	At high concentrations in vitro, clopidogrel inhibits P450 (2C9).  Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
clopidogrel	tolbutamide	15	15	true	positive	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  	
clopidogrel	tolbutamide	17	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel	tolbutamide	16	15	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  	
clopidogrel	heparin	3	5	false	none	Clopidogrel bisulfate potentiated the effect of aspirin on collagen-induced platelet aggregation.  Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
clopidogrel	heparin	4	5	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
clopidogrel	heparin	4	6	false	none	Clopidogrel bisulfate and aspirin have been administered together for up to one year.  Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
clopidogrel	heparin	5	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  	
clopidogrel	heparin	5	6	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
clopidogrel	heparin	6	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
clopidogrel	heparin	6	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  	
clopidogrel	heparin	7	5	false	none	Heparin                                                             In a study in healthy volunteers, clopidogrel bisulfate did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.  Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
clopidogrel	heparin	7	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  	
clopidogrel	heparin	8	6	false	none	Coadministration of heparin had no effect on inhibition of platelet aggregation induced by clopidogrel bisulfate.  Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)                                                             In healthy volunteers receiving naproxen, concomitant administration of clopidogrel bisulfate was associated with increased occult gastrointestinal blood loss.  NSAIDs and clopidogrel bisulfate should be coadministered with caution.  	
clopidogrel	heparin	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel	heparin	17	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel	heparin	16	17	false	none	Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel	heparin	18	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  The use of oral anticoagulants, non-study anti-platelet drug and chronic NSAIDs was not allowed in CURE and there are no data on their concomitant use with clopidogrel.  	
clopidogrel	insulin	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel	insulin	17	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel	insulin	16	17	false	none	Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel	insulin	18	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  The use of oral anticoagulants, non-study anti-platelet drug and chronic NSAIDs was not allowed in CURE and there are no data on their concomitant use with clopidogrel.  	
clopidogrel	cholesterol	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel	cholesterol	17	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel	cholesterol	16	17	false	none	Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
clopidogrel	cholesterol	18	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  The use of oral anticoagulants, non-study anti-platelet drug and chronic NSAIDs was not allowed in CURE and there are no data on their concomitant use with clopidogrel.  	
tolbutamide	heparin	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
tolbutamide	insulin	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
tolbutamide	cholesterol	15	17	false	none	Accordingly, clopidogrel bisulfate may interfere with the metabolism of phenytoin, tamoxifen, tolbutamide, warfarin, torsemide, fluvastatin, and many non-steroidal anti-inflammatory agents, but there are no data with which to predict the magnitude of these interactions.  Caution should be used when any of these drugs is coadministered with clopidogrel bisulfate.  In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
heparin	insulin	17	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
heparin	cholesterol	17	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
insulin	cholesterol	17	17	false	none	In addition to the above specific interaction studies, patients entered into clinical trials with clopidogrel bisulfate received a variety of concomitant medications including diuretics, beta-blocking agents, angiotensin converting enzyme inhibitors, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, hormone replacement therapy, heparins (unfractionated and LMWH) and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.  	
|endresults
